MUC16 and ovarian cancer: Olivier Colomban et al. used a Kelim model [26], which characterize the CA125 elimination rate during the first 100 days of NACT and adjuvant chemotherapy, to assess the benefit in survival with bevacizumab addition for high-risk ovarian cancer patients in ICON-7 [9].